GlassScriptPhysician profile
Prasanth N Surampudi
NPI 1538367438
$2,325.38
in general payments reported to CMS, 2019-2025
12 companies · $337 in 2025
The $337 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $252 · 2021: $123 · 2022: $325 · 2023: $532 · 2024: $229 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,098.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,098.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $659.19 | 2019-2025 | Wegovy |
| Mannkind Corporation | $382.67 | 2021-2023 | V-Go |
| Corcept Therapeutics | $333.19 | 2020-2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $205.49 | 2024-2025 | |
| Amgen INC. | $174.26 | 2025 | Tepezza |
| Abbott Laboratories | $165.20 | 2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $122.31 | 2023 | |
| Catalyst Pharmaceuticals, INC. | $97.50 | 2024 | |
| Janssen Pharmaceuticals, INC | $92.83 | 2019 | |
| Lilly USA, LLC | $92.74 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prasanth Surampudi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.